Can Zepbound, Ozempic, Wegovy or Mounjaro Cause Insomnia? What the Labels, Studies and Users Say

Short answer

Insomnia is not listed as a side effect in the US labels for Zepbound, Mounjaro, Wegovy or Ozempic, and a large health-records study found semaglutide was not linked to more insomnia than other diabetes drugs. Adverse-event reporting databases do show more insomnia reports for GLP-1 drugs than expected, which is a signal, not proof. People still describe poor sleep, often early on, and the usual suspects are night-time hunger or reflux, burping, a slightly faster heart rate, and low blood sugar in people also on insulin or a sulfonylurea. On the other side, Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity (see Zepbound for sleep apnea). Not medical advice. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Last reviewed November 7, 2026.

What the evidence shows

Why sleep can change on a GLP-1

• —Reflux, burping and fullness at night. Slower stomach emptying means a late meal can still be in the stomach at bedtime. See GLP-1 heartburn and sulfur burps.
• —A faster heart rate. The labels report average increases of 2 to 3 beats per minute on Ozempic, 2 to 4 on Mounjaro and 1 to 3 on Zepbound, and the Wegovy label asks for heart rate to be monitored. Some people notice a pounding or racing heart at night.
• —Hunger or low blood sugar. Eating far less can mean waking hungry. Shaking, sweating and a racing heart at night can be low blood sugar, mainly in people also taking insulin or a sulfonylurea, and needs prompt treatment.
• —Nausea, cramps or diarrhea that wake you. See GLP-1 stomach pain.
• —Mood and life changes. Anxiety or low mood can disrupt sleep; see GLP-1 depression and mood.

Zepbound and sleep apnea

Zepbound is approved to treat obstructive sleep apnea: the US label lists moderate to severe obstructive sleep apnea in adults with obesity as an indication, and so does the Canadian Zepbound monograph (June 11, 2026). The approval rests on the two SURMOUNT-OSA trials (Malhotra 2024): average breathing interruptions fell from about 50 per hour by 25.3 per hour without CPAP and by 29.3 per hour with CPAP, vs 5.3 and 5.5 on placebo. Full hub: Zepbound for sleep apnea. Sleep apnea is a medical diagnosis; loud snoring, gasping at night and daytime sleepiness are reasons to ask about a sleep study, not to stop a CPAP machine on your own.

Retatrutide and sleep

Many of the sleep complaints on this site come from people using retatrutide, an investigational triple agonist that is not approved anywhere and is not covered by any of the studies above. Users describe waking at 2 or 3 a.m., a raised resting heart rate and very vivid dreams. These are anonymous reports, not trial data.

When to talk to someone

• —Poor sleep most nights for more than a few weeks, or daytime sleepiness that affects driving or work: tell your prescriber or family doctor.
• —A racing or pounding heart at rest, chest pain, or fainting: get medical care promptly.
• —Night sweats, shaking or confusion if you also take insulin or a sulfonylurea: this can be low blood sugar.
• —Loud snoring, gasping or pauses in breathing at night: ask about sleep apnea testing.

What users report here

From live confessions (checked October 29, 2026). On tirzepatide, #774 says GLP-1s made their CPAP redundant, but late dinners meant burps waking them at night. The rest involve retatrutide: #96 went from sleeping 7 to 8 hours to waking at 2 a.m. and lying awake until 4 or 5, #394 says 3 a.m. waking and a higher resting heart rate started after adding it to tirzepatide, #503 woke several times a night around week 7 and plans to move to tirzepatide, #307 describes being "wired" at 2 a.m., and #762 reports a run of vivid dreams and nightmares. #826 says their early insomnia went away. Stories, not rates.